Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 98, New York, NY, USA.
Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA.
Curr Psychiatry Rep. 2022 Jul;24(7):345-351. doi: 10.1007/s11920-022-01340-5. Epub 2022 May 16.
Identifying medications that may be used as therapeutic agents for eating disorders is a longstanding focus of research, with varying degrees of success. The present review consolidates the most recent findings on pharmacological treatment of three eating disorders, including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED).
Recent research suggests that olanzapine demonstrates positive effects on weight gain among outpatients with AN. There are fewer recent advances in psychopharmacological treatment for BN and BED, likely due to the relative success of prior medication trials. Olanzapine is the first medication to safely promote weight gain among individuals with AN. Fluoxetine is FDA-approved for BN treatment, and lisdexamfetamine is FDA-approved for BED treatment. BN and BED also generally respond well to SSRIs prescribed off-label. Research on psychopharmacological treatments for other eating disorders, such as avoidant-restrictive food intake disorder and other specified feeding and eating disorders, are sorely needed.
寻找可用于治疗饮食失调的药物一直是研究的重点，虽然取得了不同程度的成功。本综述综合了关于三种饮食失调（包括神经性厌食症（AN）、神经性贪食症（BN）和暴食障碍（BED））的药物治疗的最新发现。
最近的研究表明，奥氮平对 AN 门诊患者的体重增加有积极影响。BN 和 BED 的药物治疗方面的最新进展较少，可能是由于之前药物试验的相对成功。奥氮平是第一种安全促进 AN 患者体重增加的药物。氟西汀已获得 FDA 批准用于 BN 治疗，而 lisdexamfetamine 已获得 FDA 批准用于 BED 治疗。BN 和 BED 通常也对处方的 SSRI 药物反应良好。非常需要研究治疗其他饮食失调的药物治疗，例如回避性限制型食物摄入障碍和其他特定的喂养和进食障碍。
